Egypt’s metabolic dysfunction associated steatotic liver disease: Genetic and dietary nexus, shaping artificial intelligence driven healthier future

Table 1 Different laboratory parameters among participants with metabolically dysfunction-associated steatotic liver disease and healthy controls, n (%)/median (range)/mean ± SD

Metabolically dysfunction-associated steatotic liver disease	Yes	No	P value
Lipoprotein lipase	15 (0.5-185)	18 (0.5-214)	0.062
L-carnitine	12.3 (0.1-63)	13 (0.6-58)	0.099
C-reactive protein	4 (0.3-117)	2 (0.2-39.2)	< 0.001
Aspartate aminotransferase	20 (4.5-236)	18 (9-103)	< 0.001
Alanine aminotransferase	20 (4-258)	14 (3-82)	< 0.001
Gamma-glutamyl transferase	23 (4-595)	15 (4-137)	< 0.001
Bilirubin	0.4 (0.1-2)	0.4 (0-54)	0.066
International normalized ratio	1 (0.9-10)	1.1 (1-1.1)	0.302
Homeostasis Model Assessment of Insulin Resistance	2.2 (0.1-73)	1.4 (0-20.2)	< 0.001
Fasting insulin	9.9 (0.3-279.4)	7 (0.3-45)	< 0.001
Triglycerides	120 (3.9-1086)	74 (28-409)	< 0.001
Very LDL	24 (3.1-217.2)	14.8 (5.8-81.8)	< 0.001
Thyrotropin	1.6 (0.01-100)	1.5 (0.01-9.7)	0.227
Albumin	4.7 ± 2.4	4.7 ± 0.4	0.876
Fasting blood sugar	98.3 ± 33.6	88.9 ± 23.4	< 0.001
Glycated hemoglobin (%)	5.7 ± 1.1	5.2 ± 0.7	< 0.001
Total cholesterol	205.9 ± 44.7	193.1 ± 40.2	< 0.001
High-density lipoprotein	46.4 ± 11.9	52.1 ± 13	< 0.001
LDL	132.1 ± 39	122.8 ± 34.4	< 0.001
FT3	3.3 ± 0.5	3.4 ± 1.5	0.196
FT4	1.3 ± 0.3	1.4 ± 0.5	0.003
PNPLA gene
CC	373 (65.9)	193 (34.1)	0.649
CG	261 (68.1)	122 (31.9)
GG	43 (70.5)	18 (29.5)
PNPLA alle
C alle	1007 (66.5)	508 (33.5)	0.382
G alle	347 (68.7)	158 (31.3)

FT: Free thyroxine; LDL: Low-density lipoproteins.